scholarly journals Effect of a Novel Non-steroidal Anti-inflammatory Drug (M-5011) on Cytokine Levels in Rats With Monosodium Urate Crystal-Induced Pleurisy

1999 ◽  
Vol 79 (4) ◽  
pp. 439-446 ◽  
Author(s):  
Murakami Naofumi ◽  
Aihara Shizuhiko ◽  
Iwata Kazumi ◽  
Saito Takako ◽  
Naruse Tomohiro
Keyword(s):  
Monosodium Urate ◽  
Inflammatory Drug ◽  
Cytokine Levels ◽  
Urate Crystal ◽  
Anti Inflammatory

scholarly journals POS0132 IS THE INTERCRITICAL GOUT REALLY ASYMPTOMATIC? THE INFLAMMATORY ROLE OF THE SILENT URATE CRYSTAL DEPOSITION

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 277.1-278
Author(s):  
C. Diaz-Torne ◽  
M. A. Ortiz ◽  
S. Jeria Navarro ◽  
A. Garcia-Gullien ◽  
L. Sainz ◽  
...  
Keyword(s):  
Risk Factors ◽  
Whole Body ◽  
Subclinical Inflammation ◽  
Monosodium Urate ◽  
Crystal Deposition ◽  
Secretome Analysis ◽  
Healthy Donors ◽  
Cytokine Levels ◽  
Urate Crystal ◽  
Crystal Deposit

Background:Gout is the most prevalent inflammatory arthritis. Gout is chronic inflammatory deposition disease related to an increase of cardiovascular (CV) events and mortality. Subclinical chronic inflammation has been demonstrated in this patients but not its relation with the monosodium urate (MSU) crystal deposit size and the number of CV risk factors.Objectives:To study the subclinical inflammation in intercritical gout patients and its possible relation to the estimated size of the crystal deposition and the number of CV risk factors.Methods:To analyze subclinical inflammation we performed a secretome analysis and a cytokine and adiponektine plasma levels quantification (IL-1β, IL-18, IL-6, sIL-6R, TNFα, CXCL-5, RANTES, leptin, resistin and adiponectin) in a cohort of gout patients. As nowadays it is not feasible to determinate the whole body deposit of MSU crystals we created three different MSU crystal deposit size patient groups using an indirect clinical and analytical classification to estimate it. Then we compared cytokine levels between healthy donors and gout patients. We also compared cytokine levels between the different crystal size deposition groups and studied its association to the number of CV risk factors.Results:Ninety consecutive patients attending a Crystal Arthritis Unit were studied. Mean age was 68.27 (28-101) years. 81.1% were male. Clinical gout evolution was of 10.1±9.8 years. 77.5% were on urate lowering treatment. 24% had tophaceous gout. Mean uric acid was 6.3±2.1 mg/dl with 47.1% of them being on target. Hypertension was present in 68.9%, diabetes mellitus in 18.9%, dislipemia in 48.9%, BMI>30 in 32.9%, abdominal obesity in 50% and 16.1% suffered from ischemic heart disease. From the 102 molecules studied in the secretome analysis in 56 there was at least a 20% difference between donors group and any of the deposition groups. In 74% of them gout patients secreted lower levels. IL-18, sIL-6R, RANTES, leptin and adiponectin were higher in patients than in healthy donors. IL-18, sIL6-R, RANTES and CXCL5 levels were associated to the size of the crystal deposits. IL-18, sIL-6R, RANTES and leptin were higher in gout groups with CV risk factors. IL-18, sIL6-R, RANTES and leptin were higher in gout patients with no risk factors when compared to healthy donors with no risk factors. We found no differences when comparing urate lowering treated and non-treated patients.Conclusion:Our results demonstrate that some proinflammatory cytokines and metabolic proteins are raised in intercritical gout patients. Some of them are different from the flare/inflammasome expected ones. In some cytokines this elevation is related to the size of the monosodium urate crystal deposit and/or to the number of cardiovascular risk factors. This cytokine changes could help to explain the increase of the cardiovascular events in gout patients.Disclosure of Interests:Cesar Diaz-Torne Grant/research support from: Received a grant from Grünenthal, Maria Angels Ortiz: None declared, Sicylle Jeria Navarro: None declared, Andrea Garcia-Gullien: None declared, Lluis Sainz: None declared, Hector Corominas: None declared, Silvia Vidal: None declared

Anti-inflammatory effects of traditional mixed extract of medicinal herbs (MEMH) on monosodium urate crystal-induced gouty arthritis

2017 ◽  
Vol 15 (8) ◽  
pp. 561-575 ◽  
Author(s):  
Ju-Suk Nam ◽  
Supriya Jagga ◽  
Ashish Ranjan Sharma ◽  
Joon-Hee Lee ◽  
Jong Bong Park ◽  
...  
Keyword(s):  
Gouty Arthritis ◽  
Medicinal Herbs ◽  
Monosodium Urate ◽  
Urate Crystal ◽  
Anti Inflammatory

scholarly journals Zisheng Shenqi decoction ameliorates monosodium urate crystal-induced gouty arthritis in rats through anti-inflammatory and anti-oxidative effects

2016 ◽  
Vol 14 (3) ◽  
pp. 2589-2597 ◽  
Author(s):  
Jieru Han ◽  
Ying Xie ◽  
Fangyu Sui ◽  
Chunhong Liu ◽  
Xiaowei Du ◽  
...  
Keyword(s):  
Gouty Arthritis ◽  
Monosodium Urate ◽  
Urate Crystal ◽  
Anti Inflammatory ◽  
Oxidative Effects

scholarly journals Inhibition of Monosodium Urate Crystal-Induced Inflammation by Withaferin A

2009 ◽  
Vol 11 (4) ◽  
pp. 46 ◽  
Author(s):  
Mahaboobkhan Rasool ◽  
Sonal Chandal ◽  
Evan Prince Sabina
Keyword(s):  
Lipid Peroxidation ◽  
Lactate Dehydrogenase ◽  
Lysosomal Enzymes ◽  
Inflammatory Mediator ◽  
Gouty Arthritis ◽  
Withaferin A ◽  
Polymorphonuclear Leucocytes ◽  
Monosodium Urate ◽  
Urate Crystal ◽  
Anti Inflammatory

ABSTRACT Purpose. Gouty arthritis is a characteristically intense acute inflammatory reaction resulting from the formation of sodium urate crystals in the joint cavity. In the present study, the effect of withaferin A, a steroidal lactone was investigated on monosodium urate crystal-induced inflammation in mice; an experimental model for gouty arthritis and compared it with that of the non-steroidal anti-inflammatory drug, indomethacin. Methods. Paw volume and levels/activities of lysosomal enzymes, lipid peroxidation, anti-oxidant status and inflammatory mediator TNF-α were determined in control and monosodium urate crystal-induced mice. The levels of β-glucuronidase and lactate dehydrogenase were also measured in monosodium urate crystal-incubated polymorphonuclear leucocytes (PMNL). Results. Paw volume, the levels of lysosomal enzymes, lipid peroxidation, and inflammatory mediator tumour necrosis factor-α were found to be increased significantly and the activities of antioxidant status were in turn decreased in monosodium urate crystal-induced mice; however these changes were reverted back to near normal levels in withaferin A (30 mg/kg/b.wt, i.p.) treated monosodium urate crystal-induced mice. In addition, β-glucuronidase and lactate dehydrogenase level were reduced in withaferin A (100μg/ml) treated monosodium urate crystal-incubated polymorphonuclear leucocytes. Conclusion. The present findings clearly indicated that withaferin A exerted a strong anti-inflammatory effect against gouty arthritis.

scholarly journals Evaluation of the anti-gout effect of Sonchus Arvensis on monosodium urate crystal-induced gout arthritis via anti-inflammatory action - an in vivo study

2021 ◽  
Author(s):  
Nita Parisa ◽  
Rachmat Hidayat ◽  
Ziske Maritska ◽  
Bintang Arroyantri Prananjaya
Keyword(s):  
Ethyl Acetate ◽  
Synovial Tissue ◽  
Inflammatory Cells ◽  
Positive Control ◽  
Control Group ◽  
Monosodium Urate ◽  
Water Fraction ◽  
Urate Crystal ◽  
Anti Inflammatory ◽  
Sonchus Arvensis

Background and aims. Sonchus arvensis is an Indonesian plant with strong therapeutic effects. Various studies have shown that this plant is useful in treating kidney stone disorders, and recent studies have shown that S. arvensis extract can reduce inflammation caused by monosodium urate crystal deposition in the synovial tissue . This study was aimed to explore the extract of Sonchus arvensis, via fractionation, to optimize the specific content of S. arvensis with anti-inflammatory potential in gout arthritis. Methods. The study included 30 rats (Rattus norvegicus) Wistar strain obtained from the Eureka Research Laboratory (Palembang, Indonesia) weighing between 200 - 250 grams. After one week of acclimatization, the rats were randomly divided into six groups, each group containing five animals; normal control group, monosodium urate group (negative control), colchicine group, hexane fraction of S. arvensis group, ethyl-acetate fraction of S. arvensis group and water fraction group. Before monosodium urate administration, rats in the colchicine group, as a positive control group, were given orally for seven days with 0.28 mg/kg/day colchicine. IL-1β levels in joint synovial fluid were examined with Rat ELISA interleukin-1β. Results. S. arvensis water fraction showed the most significant reduction in inflammatory cells compared to the hexane or ethyl acetate fractions. The water fraction of  S. arvensis group had an equal effect with positive control in reducing the infiltration of inflammatory cells in the synovial tissue.  Conclusion. Sonchus arvensis water fraction has anti-gout effects in monosodium urate-induced gout arthritis in rats by decreasing the inflammatory response in the synovial joint.

scholarly journals LC-MS Analysis of Serum for the Metabolomic Investigation of the Effects of Pulchinenoside b4 Administration in Monosodium Urate Crystal-Induced Gouty Arthritis Rat Model

Molecules ◽  
2019 ◽  
Vol 24 (17) ◽  
pp. 3161
Author(s):  
Shang Lyu ◽  
Ruowen Ding ◽  
Peng Liu ◽  
Hui OuYang ◽  
Yulin Feng ◽  
...  
Keyword(s):  
Rat Model ◽  
Clinical Symptoms ◽  
Biological Activities ◽  
Gouty Arthritis ◽  
Joint Inflammation ◽  
Ultra Performance Liquid Chromatography ◽  
Monosodium Urate ◽  
Wide Range ◽  
Urate Crystal ◽  
Anti Inflammatory

Gouty arthritis (GA) is commonly caused by deposition of monosodium urate (MSU) crystals within the joint capsule, bursa, cartilage, bone, or other periarticular tissues after chronic hyperuricemia. Clinically, GA is characterized by acute episodes of joint inflammation, which is most frequently encountered in the major joints, and also has a significant impact on quality of life. Pulchinenoside b4(P-b4) has a wide range of biological activities, including antitumor, anti-inflammatory, antiviral and immunomodulatory activities. Currently, the anti-GA activity and metabolomic profiles after being treated by P-b4 have not been reported. In this paper, for the first time, we have performed a non-targeted metabolomics analysis of serum obtained from an MSU crystal-induced GA rat model intervened by P-b4, using ultra-performance liquid chromatography coupled to quadrupole time-of-flight tandem mass spectrometry. In this study, the main pharmacodynamics of different dosing methods and dosages of P-b4 was firstly investigated. Results have shown that P-b4 possesses high anti-inflammatory activity. These results demonstrated changes in serum metabolites with 32 potential biomarkers. Arachidonic acid, sphingolipid, and glycerophospholipid metabolism are considered to be the most relevant metabolic pathway with P-b4 treatment effect in this study. Moreover, the changes of metabolites and the self-extinction of model effects within 24 h reveals important information for GA diagnostic criteria: The regression of clinical symptoms or the decline of some biochemical indicators cannot be regarded as the end point of GA treatment. Furthermore, our research group plans to conduct further metabolomics research on the clinical course of GA.

Sign in / Sign up

Export Citation Format

Share Document